DMARD composition within the concurrent and biologic-alone groups. Data are shown as n (%) of patients, unless stated otherwise.
| Medication | Concurrent, n = 102 | Biologic Alone, n = 206 |
|---|---|---|
| Biologic DMARD | ||
| Anti-TNF | 75 (73.5) | 146 (70.9) |
| Adalimumab | 9 (8.8) | 18 (8.7) |
| Certolizumab | 8 (7.8) | 8 (3.4) |
| Etanercept | 24 (23.5) | 56 (27.2) |
| Golimumab | 20 (19.6) | 22 (10.7) |
| Infliximab | 14 (13.7) | 42 (20.4) |
| Other mechanisms | 27 (26.5) | 60 (29.1) |
| Abatacept | 14 (13.7) | 27 (13.1) |
| Anakinra | 0 (0) | 0 (0) |
| Rituximab | 3 (2.9) | 7 (3.4) |
| Tocilizumab | 9 (8.8) | 25 (12.1) |
| Ustekinumab | 1 (1.0) | 1 (0.5) |
| Conventional DMARD* | 81 (79.4) | 190 (92.2) |
| Hydroxychloroquine | 11 (5.3) | 18 (8.7) |
| Leflunomide | 20 (19.6) | 42 (20.4) |
| Methotrexate | 50 (49.0) | 130 (63.4) |
| Mean (SD) dose, mg/week | 15.0 (5.6) | 15.6 (4.8) |
| Prednisone | 21 (20.6) | 15 (7.4) |
| Mean (SD) dose, mg/week | 7.9 (7.6) | 7.6 (4.1) |
↵* Other medications included in the analysis were minocycline, sulfasalazine, tofacitinib, azathioprine, cyclophosphamide, and mycophenolate mofetil. For both groups, patients were not taking these medications during the study period. DMARD: disease-modifying antirheumatic drug; TNF: tumor necrosis factor.